A B S T R A C T In the course of studying antinuclear antibodies in the rheumatic diseases, a new precipitin reaction (provisionally referred to as PM-1) was observed between calf thymus nuclear extract and polymyositis sera. Objectives of this study were to further define the immunologic nature of this reaction and to determine its specificity for polymyositis. Immunodiffusion studies using calf thymus nuclear extract revealed the PM-1 precipitin line in 17 of 28 patients with polymyositis. This reaction was not produced by sera of 460 patients with other diseases. Enzyme and heat treatments ofthe nuclear extract showed that PM-I was distinct from native DNA, ribonucleoprotein, and Sm antigens. Fractionation of PM-i-positive serum by 30% ammonium sulphate and Sephadex G-200 chromatography revealed that the factor producing the PM-1 precipitin reaction was in a serum fraction which showed only IgG by immunoelectrophoresis against anti-whole human serum. Because of the apparent strong specificity, the PM-1 system may represent a marker antibody for polymyositis.
Received for publication 12 August 1976 and in revised form 7 October 1976. rheumatic diseases. The findings of circulating antibody to native DNA help to establish a diagnosis of systemic lupus erythematosus (1) , and antibody to nuclear ribonucleoprotein (RNP)' is helpful in the diagnosis of mixed connective tissue disease (2) . In polymyositis, however, there has been no consistent serological finding which is sufficiently sensitive and specific to be useful as a diagnostic test.
Fluorescent antinuclear antibody tests have been found to be positive to a variable degree, ranging from 6 to 30% in different studies of polymyositis (3, 4) . However, the specific antigen involved in the nuclear staining was not identified in these studies. In another study, an IgG antibody which reacted with capillary walls in mouse kidney was detected in the sera of patients with a number of rheumatic diseases including dermatopolymyositis (5) . In the course of studying the correlation of various antinuclear antibodies with clinical characteristics in the rheumatic diseases, we have observed a new precipitin reaction with calfthymus nuclear extract which appears to be specific for polymyositis-dermatomyositis.
METHODS
Sera of patients were collected during hospitalization or clinic visits at this and other medical centers and frozen in small aliquots before testing. A crude calf thymus nuclear extract (CTNE) (6), DNA (7) , and extractable nuclear antigen (2) were prepared according to published methods. Native DNA and extractable nuclear antigen were used in passive hemagglutination (1) .
' Abbreviations uised in this paper: CTNE, Calf thymus nuclear extract; RNP, ribonucleoprotein. Table I lists various enzymatic and physical treatments performed on the CTNE and their effect on the precipitin reactions, which further demonstrates that PM-1, RNP, and Sm are different antigens. The PM-1 antigen was sensitive to trypsin and heating at 56°C for 1 h, but was resistant to DNase and RNase digestion. Fractionation of PM-i-positive serum by 30% ammonium sulfate precipitation and Sephadex G-200 chromatography revealed that the factor produicing the PM-1 precipitin reaction was in a serum fraction which showed only IgG by immunoelectrophoresis against anti-whole human serum.
As shown in Table II , 17 of 28 patients with polymyositis, dermatomyositis, or polymyositis-scleroderma overlap (61%) were positive for the PM-1 reaction. Serial studies over a 5-yr period on 10 of these polymyositis patients, 5 positive and 5 negative for the PM-I reaction, showed that if PM-I was present, it remained whether or not the disease was active or in remission. Likewise, if PM-1 was not present at the time the patient was first seen it remained absent regardless of the clinical course. Other groups of patients studied including 169 with mixed connective tissue disease, 100 with systemic lupus erythematosus, 30 with scleroderma, 30 with rheumatoid arthritis, 10 with osteoarthritis, 21 with other rheumatic diseases, and 100 other hospitalized patients were uniformly negative for the PM-1 precipitin reaction.
Fluorescent antinuclear antibody tests were performed on all 28 patients with polymyositis. 8 of the 17 It is possible, because of the similarity in physiochemical characteristics of the antigen, that the same system is being described in these two independent investigations. However, the studies differ with respect to the incidence ofthe antibody in patients with dermatomyositis. We 
